期刊
CELL DEATH & DISEASE
卷 12, 期 7, 页码 -出版社
SPRINGERNATURE
DOI: 10.1038/s41419-021-03909-z
关键词
-
类别
资金
- Fondazione Umberto Veronesi
Extracellular vesicles (EVs) and their cargo are potential cancer biomarkers for liquid biopsy, and using antibody-based proteomic technology can help identify tumor-specific protein profiles in EVs. The analysis of EVs from prostate cancer patients' serum has shown promising results for tumor diagnosis and prognosis, indicating the potential of this innovative approach in translational medicine.
Extracellular vesicles (EVs) and their cargo represent an intriguing source of cancer biomarkers for developing robust and sensitive molecular tests by liquid biopsy. Prostate cancer (PCa) is still one of the most frequent and deadly tumor in men and analysis of EVs from biological fluids of PCa patients has proven the feasibility and the unprecedented potential of such an approach. Here, we exploited an antibody-based proteomic technology, i.e. the Reverse-Phase Protein microArrays (RPPA), to measure key antigens and activated signaling in EVs isolated from sera of PCa patients. Notably, we found tumor-specific protein profiles associated with clinical settings as well as candidate markers for EV-based tumor diagnosis. Among others, PD-L1, ERG, Integrin-beta 5, Survivin, TGF-beta, phosphorylated-TSC2 as well as partners of the MAP-kinase and mTOR pathways emerged as differentially expressed endpoints in tumor-derived EVs. In addition, the retrospective analysis of EVs from a 15-year follow-up cohort generated a protein signature with prognostic significance. Our results confirm that serum-derived EV cargo may be exploited to improve the current diagnostic procedures while providing potential prognostic and predictive information. The approach proposed here has been already applied to tumor entities other than PCa, thus proving its value in translational medicine and paving the way to innovative, clinically meaningful tools.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据